Nucleome Therapeutics Overview

  • Founded
  • 2019

Founded
  • Status
  • Private

  • Employees
  • 21

Employees
  • Latest Deal Type
  • Seed

  • Latest Deal Amount
  • $6.43M

  • Investors
  • 1

Nucleome Therapeutics General Information

Description

Developer of a therapeutics technology platform designed for the unique ability to connect disease-linked variants in the dark matter of the genome. The company platform creates high-resolution 3D genome structure maps and enables variant functional validation at scale in primary cell types, enabling professionals to get genetically guided therapeutic to provide improved patient outcomes.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Discovery Tools (Healthcare)
Other Industries
Drug Discovery
Other Healthcare Technology Systems
Biotechnology
Primary Office
  • BioEscalator The Innovation Building
  • The Old Road Campus, Roosevelt Drive, Headington
  • Oxford OX3 7FZ
  • England, United Kingdom

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Nucleome Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
1. Seed Round 08-Aug-2019 $6.43M 00.000 000.00 Completed Generating Revenue
To view Nucleome Therapeutics’s complete valuation and funding history, request access »

Nucleome Therapeutics Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
A Ordinary 0,000,000 00.000000 00.00 00.00 00 00.00 00.000
To view Nucleome Therapeutics’s complete cap table history, request access »

Nucleome Therapeutics Executive Team (4)

Name Title Board Seat Contact Info
Danuta Jeziorska Ph.D Co-Founder, Chief Executive Officer & Board Member
Nigel Clark Ph.D Chief Business Officer
James Hughes Co-Founder & Board Member
James Davies Co-Founder, Board Member & Board Observer
To view Nucleome Therapeutics’s complete executive team members history, request access »

Nucleome Therapeutics Board Members (7)

Name Representing Role Since
Danuta Jeziorska Ph.D Nucleome Therapeutics Co-Founder, Chief Executive Officer & Board Member 000 0000
James Davies Nucleome Therapeutics Co-Founder, Board Member & Board Observer 000 0000
James Hughes Nucleome Therapeutics Co-Founder & Board Member 000 0000
Jonathan Hepple Ph.D Self Board Member & OSI Advisor 000 0000
Matthew Carpenter Ph.D Self Board Observer 000 0000
You’re viewing 5 of 7 board members. Get the full list »

Nucleome Therapeutics Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Nucleome Therapeutics Investors (1)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Oxford Science Enterprises University Minority 000 0000 000000 0
To view Nucleome Therapeutics’s complete investors history, request access »